Visgeneer (4197) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Visgeneer (4197) has a cash flow conversion efficiency ratio of -0.060x as of June 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-11.86 Million ≈ $-373.78K USD) by net assets (NT$197.35 Million ≈ $6.22 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 4197 market cap overview for the company's overall valuation and market capitalisation.
Visgeneer - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Visgeneer's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Visgeneer Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Visgeneer ranked by their cash flow conversion efficiency. Explore Visgeneer earnings quality ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
BRADDA HEAD LITHIUM O.N.
F:8CD1
|
0.059x |
|
XTL Biopharmaceuticals Ltd ADR
NASDAQ:XTLB
|
-0.369x |
|
SOLUTIANCE AG NA O.N.
F:SLSA
|
N/A |
|
Nuvotec
KQ:060260
|
-0.075x |
|
ChargePanel AB
ST:CHARGE
|
-0.513x |
|
Winfarm
PA:ALWF
|
0.152x |
|
Euro Manganese Inc
V:EMN
|
3.655x |
|
Bengal Energy Ltd
TO:BNG
|
-0.004x |
Annual Cash Flow Conversion Efficiency for Visgeneer (2012–2025)
The table below shows the annual cash flow conversion efficiency of Visgeneer from 2012 to 2025. View Visgeneer stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | NT$199.09 Million ≈ $6.27 Million |
NT$13.37 Million ≈ $421.10K |
0.067x | +227.39% |
| 2024-12-31 | NT$193.84 Million ≈ $6.11 Million |
NT$-10.22 Million ≈ $-321.86K |
-0.053x | -184.52% |
| 2023-12-31 | NT$211.57 Million ≈ $6.67 Million |
NT$13.19 Million ≈ $415.62K |
0.062x | -66.90% |
| 2022-12-31 | NT$231.16 Million ≈ $7.28 Million |
NT$43.55 Million ≈ $1.37 Million |
0.188x | +234.16% |
| 2021-12-31 | NT$218.81 Million ≈ $6.89 Million |
NT$12.34 Million ≈ $388.65K |
0.056x | +62.41% |
| 2020-12-31 | NT$218.00 Million ≈ $6.87 Million |
NT$7.57 Million ≈ $238.40K |
0.035x | +164.63% |
| 2019-12-31 | NT$217.39 Million ≈ $6.85 Million |
NT$-11.68 Million ≈ $-367.83K |
-0.054x | -415.42% |
| 2018-12-31 | NT$249.15 Million ≈ $7.85 Million |
NT$-2.60 Million ≈ $-81.79K |
-0.010x | +87.57% |
| 2017-12-31 | NT$281.04 Million ≈ $8.85 Million |
NT$-23.55 Million ≈ $-742.02K |
-0.084x | -182.83% |
| 2016-12-31 | NT$311.69 Million ≈ $9.82 Million |
NT$31.54 Million ≈ $993.59K |
0.101x | +0.27% |
| 2015-12-31 | NT$315.69 Million ≈ $9.95 Million |
NT$31.86 Million ≈ $1.00 Million |
0.101x | +198.67% |
| 2014-12-31 | NT$309.25 Million ≈ $9.74 Million |
NT$10.45 Million ≈ $329.17K |
0.034x | -78.76% |
| 2013-12-31 | NT$285.60 Million ≈ $9.00 Million |
NT$45.42 Million ≈ $1.43 Million |
0.159x | -36.02% |
| 2012-12-31 | NT$250.23 Million ≈ $7.88 Million |
NT$62.20 Million ≈ $1.96 Million |
0.249x | -- |
About Visgeneer
Visgeneer Inc. engages in the provision of health solutions in the fields of medical device, cosmetics and skin care, Zeaxanthin, and cancer gene diagnostics in Europe and Asia. The company offers blood glucose and ketone, uric acid, and cholesterol monitoring systems. It also provides functional masks, such as wood pulp mask, invisible mask, black mask, pure cloth mask, and bio cellulose mask; f… Read more